Zymeworks saw rising retail attention after analysts raised price targets, citing its pivot to a royalty-focused model and strong new Phase 3 Ziihera cancer data. The results improved confidence ahead of key regulatory milestones. A $125 million buyback and expected milestone payments are projected to support the companies operations well past 2028.